Literature DB >> 9739060

Tumor immunity and autoimmunity induced by immunization with homologous DNA.

L W Weber1, W B Bowne, J D Wolchok, R Srinivasan, J Qin, Y Moroi, R Clynes, P Song, J J Lewis, A N Houghton.   

Abstract

The immune system can recognize self antigens expressed by cancer cells. Differentiation antigens are prototypes of these self antigens, being expressed by cancer cells and their normal cell counterparts. The tyrosinase family proteins are well characterized differentiation antigens recognized by antibodies and T cells of patients with melanoma. However, immune tolerance may prevent immunity directed against these antigens. Immunity to the brown locus protein, gp75/ tyrosinase-related protein-1, was investigated in a syngeneic mouse model. C57BL/6 mice, which are tolerant to gp75, generated autoantibodies against gp75 after immunization with DNA encoding human gp75 but not syngeneic mouse gp75. Priming with human gp75 DNA broke tolerance to mouse gp75. Immunity against mouse gp75 provided significant tumor protection. Manifestations of autoimmunity were observed, characterized by coat depigmentation. Rejection of tumor challenge required CD4(+) and NK1.1(+) cells and Fc receptor gamma-chain, but depigmentation did not require these components. Thus, immunization with homologous DNA broke tolerance against mouse gp75, possibly by providing help from CD4(+) T cells. Mechanisms required for tumor protection were not necessary for autoimmunity, demonstrating that tumor immunity can be uncoupled from autoimmune manifestations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9739060      PMCID: PMC509109          DOI: 10.1172/JCI4004

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Sorting and secretion of a melanosome membrane protein, gp75/TRP1.

Authors:  Y Xu; V Setaluri; Y Takechi; A N Houghton
Journal:  J Invest Dermatol       Date:  1997-12       Impact factor: 8.551

2.  Fc receptors are required in passive and active immunity to melanoma.

Authors:  R Clynes; Y Takechi; Y Moroi; A Houghton; J V Ravetch
Journal:  Proc Natl Acad Sci U S A       Date:  1998-01-20       Impact factor: 11.205

3.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

4.  The role of tyrosinase in autoimmune vitiligo.

Authors:  Y H Song; E Connor; Y Li; B Zorovich; P Balducci; N Maclaren
Journal:  Lancet       Date:  1994-10-15       Impact factor: 79.321

5.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors:  T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

6.  Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization.

Authors:  H M Ross; L W Weber; S Wang; G Piskun; R Dyall; P Song; Y Takechi; J Nikolić-Zugić; A N Houghton; J J Lewis
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

7.  A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.

Authors:  E Stockert; E Jäger; Y T Chen; M J Scanlan; I Gout; J Karbach; M Arand; A Knuth; L J Old
Journal:  J Exp Med       Date:  1998-04-20       Impact factor: 14.307

8.  The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product.

Authors:  S Vijayasaradhi; B Bouchard; A N Houghton
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

9.  Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.

Authors:  A N Houghton; M Eisinger; A P Albino; J G Cairncross; L J Old
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

10.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.

Authors:  V Brichard; A Van Pel; T Wölfel; C Wölfel; E De Plaen; B Lethé; P Coulie; T Boon
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more
  55 in total

1.  Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.

Authors:  G Zeng; C E Touloukian; X Wang; N P Restifo; S A Rosenberg; R F Wang
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

Review 2.  Immune recognition of self in immunity against cancer.

Authors:  Alan N Houghton; José A Guevara-Patiño
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 3.  Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy.

Authors:  Michael Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

4.  Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.

Authors:  Brian A Ginsberg; Humilidad F Gallardo; Teresa S Rasalan; Matthew Adamow; Zhenyu Mu; Sapna Tandon; Barrett B Bewkes; Ruth-Ann Roman; Paul B Chapman; Gary K Schwartz; Richard D Carvajal; Katherine S Panageas; Stephanie L Terzulli; Alan N Houghton; Jianda D Yuan; Jedd D Wolchok
Journal:  Clin Cancer Res       Date:  2010-07-20       Impact factor: 12.531

5.  Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma.

Authors:  Jack C F Liao; Polly Gregor; Jedd D Wolchok; Francesca Orlandi; Diane Craft; Carrie Leung; Alan N Houghton; Philip J Bergman
Journal:  Cancer Immun       Date:  2006-04-21

6.  Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.

Authors:  Wolfgang W Leitner; Elke S Bergmann-Leitner; Leroy N Hwang; Nicholas P Restifo
Journal:  Vaccine       Date:  2006-05-06       Impact factor: 3.641

7.  Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Authors:  Yvonne M Saenger; Yanyun Li; Karoline C Chiou; Brian Chan; Gabrielle Rizzuto; Stephanie L Terzulli; Taha Merghoub; Alan N Houghton; Jedd D Wolchok
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

8.  Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

Authors:  Adam D Cohen; Adi Diab; Miguel-Angel Perales; Jedd D Wolchok; Gabrielle Rizzuto; Taha Merghoub; Deonka Huggins; Cailian Liu; Mary Jo Turk; Nicholas P Restifo; Shimon Sakaguchi; Alan N Houghton
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

9.  Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model.

Authors:  Jan Aleksander Kraśko; Karolina Žilionytė; Adas Darinskas; Neringa Dobrovolskienė; Agata Mlynska; Svetlana Riabceva; Iosif Zalutsky; Marina Derevyanko; Vladimir Kulchitsky; Olga Karaman; Natalia Fedosova; Tatiana Vasyliyvna Symchych; Gennady Didenko; Vasyl Chekhun; Marius Strioga; Vita Pašukonienė
Journal:  Oncol Lett       Date:  2018-02-05       Impact factor: 2.967

Review 10.  Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.

Authors:  Jeanne Menez-Jamet; Catherine Gallou; Aude Rougeot; Kostas Kosmatopoulos
Journal:  Ann Transl Med       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.